Trials / Completed
CompletedNCT00345137
Effects of Systemic NO-Inhibition on Renal Hemodynamics in Patiens With Polycystic Kidney Disease and Chronic Glomerulonephritis
Phase 1 Study of Systemic Effects of Ng-Monomethyl-L-Arginine on Renal Hemodynamics in Patients With Polycystic Kidney Disease and Chronic Glomerulonephritis
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 75 (planned)
- Sponsor
- Regional Hospital Holstebro · Academic / Other
- Sex
- All
- Age
- 20 Years – 60 Years
- Healthy volunteers
- Accepted
Summary
The study tests the hypothesis that systemic and renal nitric oxide availability is changed in polycystic kidney disease and chronic glomerulonephritis.
Detailed description
In a randomized, placebo controlled design, the effects of systemic treatment with monomethyl-L-arginine are studied on: 1. renal hemodynamics 2. renal sodium excretion and lithium clearance 3. blood pressure and heart rate 4. plasma levels of vasoactive hormones in patients with adult polycystic kidney disease and chronic glomerulonephrits. The results are compared with a group of healthy control subjects
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ng-monomethyl-L-arginine (drug) |
Timeline
- First posted
- 2006-06-27
- Last updated
- 2006-06-27
Source: ClinicalTrials.gov record NCT00345137. Inclusion in this directory is not an endorsement.